Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Biotechnology

Healthcare
$41.37 +3.19%

+$1.11 today

Market cap
$4.45B
Beta
0.30
P/E (TTM)
-21.9
EPS (TTM)
-$1.64
52W Low $12.15High $40.77

Volume 0.87M

Average 1.32M

EWTX Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Edgewise Therapeutics, Inc.NASDAQ: EWTX

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) remains negative

Q3 FY2026 weighted avg shares (diluted) was 0 shares, compared with 105.49M shares a year earlier. Trailing-twelve-month weighted avg shares (diluted) was 79.43M shares. Over 3 fiscal years it compounded at +24.3% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly weighted avg shares (diluted) holds near 0 shares or moves back toward the trailing-twelve-month quarterly average of 19.86M shares.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
0-100.0% QoQ
Last fiscal yearDec 2025
102.93M+11.4% YoY
LTMSep 2026
79.43M-20.2% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+11.4%——
3-year CAGR+24.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
102.93M USD
Year-over-year change
+11.4%
4-year CAGR
+20.1%

Weighted Avg Shares (Diluted) vs competitors

How EWTX compares with its peers on the latest reported figures

  • EWTX's LTM Sep 2026 weighted avg shares (diluted) of 79.43M shares is the 5th highest of the 10 companies compared; the peer median is 78.18M shares.
  • Its year-over-year change of -20.2% is the lowest of 10, against a peer median of +15.0%.
  • Over three fiscal years its annual growth of +24.3% compares with a peer median of +23.7%.
EWTX Competitors Peer median
Weighted Avg Shares (Diluted) for EWTX and competitors
Company Period LTM YoY 3-year CAGR
DYNDyne Therapeutics, Inc.LTM Jun 2026150.19M +40.8%+35.2%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026108.39M +6.9%+6.2%
SLDBSolid Biosciences Inc.LTM Mar 202698.28M +94.3%+117.4%
PTCTPTC Therapeutics, Inc.LTM Jun 202685.59M +7.4%+7.2%
EWTXEdgewise Therapeutics, Inc.LTM Sep 202679.43M -20.2%+24.3%
LRMRLarimar Therapeutics, Inc.LTM Mar 202678.18M +22.5%+41.5%
STOKStoke Therapeutics, Inc.LTM Mar 202659.6M +4.3%+15.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 202649.43M +35.6%+23.7%
TRDAEntrada Therapeutics, Inc.LTM Mar 202641.5M +3.6%+9.8%
PEPGPepGen Inc.LTM Mar 202637.49M +15.0%+39.2%
Peer median (excluding EWTX) 78.18M+15.0%+23.7%

Competitors are the stored peer set for EWTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00002.27M
Gross Profit0000(2.27M)
Gross Margin—————
Research & Development32.19M54.03M90.91M126.97M151.39M
Selling, General & Admin11.03M17.63M23.45M31.87M40.02M
Operating Expenses43.22M71.66M114.36M158.83M189.14M
Depreciation & Amortization272K538K1.73M2.29M2.27M
EBITDA(42.54M)(63.08M)(98.43M)(131.52M)(165.53M)
EBITDA Margin—————
Operating Income(43.22M)(71.66M)(114.36M)(158.83M)(191.41M)
Operating Margin—————
Interest Income402K2.66M14.19M25.02M23.61M
Interest Expense04.02M000
Other Income / Expenses402K4.02M14.19M25.02M23.61M
Income Before Tax(42.81M)(67.64M)(100.16M)(133.81M)(167.8M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(42.81M)(67.64M)(100.16M)(133.81M)(167.8M)
Net Margin—————
EPS (Basic)(0.86)(1.26)(1.57)(1.45)(1.63)
EPS (Diluted)(0.86)(1.26)(1.57)(1.45)(1.63)
Weighted Avg Shares49.5M53.59M63.72M92.41M102.93M
Weighted Avg Shares (Diluted)49.5M53.59M63.72M92.41M102.93M

Edgewise Therapeutics, Inc.

NASDAQ:EWTX

Intrinsic Alpha fair value

Locked

Current Price

$41.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.